Comparison of the 3‐Year Continuation Rate and Discontinuation Factors Between Vibegron and Mirabegron in Patients With Overactive Bladder: A Retrospective Follow‐Up Study in a Rehabilitation Hospital in Japan

Documenti analoghi

• Safety and Effectiveness of Vibegron in Japanese Patients With Overactive Bladder: A Japanese Postmarketing Survey
  di: Shoko Yoshimura, et al.
  Pubblicazione: (2024)
• Impact of Lower Urinary Tract Symptoms on Daily Life in Individuals With Co‐Existence Overactive and Underactive Bladder, Overactive Bladder, and Underactive Bladder
  di: Noritoshi Sekido, et al.
  Pubblicazione: (2025)
• Factors associated with symptomatic urinary tract infection in persons with spinal cord lesions who perform clean intermittent catheterization with single‐use catheters
  di: Noritoshi Sekido, et al.
  Pubblicazione: (2024)
• Efficacy and Safety of Vibegron Add‐On Therapy for Persistent Overactive Bladder Symptoms in Benign Prostatic Hyperplasia Patients With α 1 ‐Blocker Treatment: A Multi‐Center Prospective Randomized Controlled Study ( VATON Study)
  di: Masaki Yoshida, et al.
  Pubblicazione: (2026)
• Serum Serotonin Levels as a Potential Risk Factor for Overactive Bladder in a Community‐Dwelling Population: A Four‐Year Longitudinal Study
  di: Takafumi Fukushima, et al.
  Pubblicazione: (2025)